Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)

NCT07223203 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT07223203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
February 3, 2026
Completion date
June 12, 2031
Enrollment
125 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

hattr-pn, hereditary transthyretin-mediated amyloidosis with polyneuropathy